These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26120575)

  • 1. Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes.
    Asias BD; Stock EM; Small NL; Getchell KE; Patel JR; Krause JD; Cavness S; Dzenowski CL; Ta M
    J Diabetes Metab Disord; 2015; 14():53. PubMed ID: 26120575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
    Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
    Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Comparative Dosing and Glycemic Control of Intermediate and Long-Acting Insulins in Adult Patients With Type 1 and 2 Diabetes Mellitus.
    Kabakov A; Merker A
    J Pharm Technol; 2022 Feb; 38(1):46-53. PubMed ID: 35141727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus.
    Kusunoki Y; Katsuno T; Miyakoshi K; Ikawa T; Nakae R; Ochi F; Tokuda M; Akagami T; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
    Diabetes Ther; 2013 Dec; 4(2):461-72. PubMed ID: 24282104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Unit Equivalency of Insulin Glargine to Insulin Detemir in an Acute Care Setting.
    Cook EA; Gill T; Taylor S
    J Pharm Technol; 2018 Dec; 34(6):239-243. PubMed ID: 34861013
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
    Valentine WJ; Palmer AJ; Erny-Albrecht KM; Ray JA; Cobden D; Foos V; Lurati FM; Roze S
    Adv Ther; 2006; 23(2):191-207. PubMed ID: 16751153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients.
    Jakobsen M; Dalsgaard M; Hørmann M; Møller DV
    BMC Endocr Disord; 2012 Sep; 12():21. PubMed ID: 23009558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
    Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
    Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial.
    Bilz S; Flückiger M; Meienberg F; Falconnier C; Keller U; Puder JJ
    PLoS One; 2018; 13(8):e0202007. PubMed ID: 30114246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
    Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
    Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic Variability With Insulin Glargine Versus Detemir in Hospitalized Patients With Diabetes.
    George J; Giuliano CA; Hartner CL
    J Pharm Pract; 2021 May; ():8971900211017867. PubMed ID: 34002663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.
    Davis KL; Tangirala M; Meyers JL; Wei W
    Curr Med Res Opin; 2013 Sep; 29(9):1083-91. PubMed ID: 23734906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
    Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
    Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
    Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
    Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK.
    Husemoen LLN; Mørch LS; Christensen PK; Hartvig NV; Feher MD
    Diabetes Ther; 2021 May; 12(5):1299-1311. PubMed ID: 33721211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.